The Challenge of Demonstrating Cost Effectiveness in Alzheimer's Disease in England: Case Study of a Hypothetical Emerging Treatment


Treharne C1, Spencer C2
1Mtech Access, London, UK, 2Mtech Access, Manchester, LAN, UK

Presentation Documents

OBJECTIVES: Alzheimer’s disease (AD) is a progressive neurological disease, characterised by deterioration in patient cognition, function and behaviour. No disease-modifying treatments are currently approved for use in the UK, with current practice focused on symptom management. This analysis aimed to identify cost-effective treatment profiles for a hypothetical emerging treatment (HET) in patients with mild AD from an English NHS perspective.

METHODS: A lifetime Markov model was developed to estimate costs and health outcomes for patients with AD treated with current standard of care (donepezil and memantine) versus a HET. The model structure was based on the Institute for Clinical and Economic Review (ICER) evidence review for aducanumab, with five health states characterising the severity of AD (mild cognitive impairment (MCI) due to AD, mild AD, moderate AD, severe AD, and death). Setting of care (community or long-term care) was also tracked. Treatment was assumed to slow disease progression, modelled via a hazard ratio (HR). Clinical data, cost (direct medical) and utility inputs were obtained from the literature and UK data sources. Two-way sensitivity analysis was used to explore cost-effective treatment profiles, and one-way sensitivity analysis was used to determine drivers of cost effectiveness.

RESULTS: For an emerging treatment with HRs on progression of 0.9, 0.7, and 0.5, the maximum annual treatment cost at a willingness-to-pay threshold of £30,000 was £825, £2,550, and £4,400, respectively. The drivers of cost effectiveness were treatment efficacy, annual treatment cost, inclusion of social care costs, and utility values.

CONCLUSIONS: Using established AD modelling approaches, a range of cost-effective profiles were identified for a HET. The analysis suggests that a commercial arrangement would likely be required for a HET to be considered cost-effective from an English NHS perspective. Drivers of cost effectiveness in this AD analysis were found to be consistent with those detailed in literature.

Conference/Value in Health Info

2022-11, ISPOR Europe 2022, Vienna, Austria

Value in Health, Volume 25, Issue 12S (December 2022)




Clinical Outcomes, Economic Evaluation

Topic Subcategory

Comparative Effectiveness or Efficacy, Cost-comparison, Effectiveness, Utility, Benefit Analysis


SDC: Neurological Disorders, STA: Drugs, STA: Generics

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now